209 related articles for article (PubMed ID: 23690471)
1. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
3. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
4. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
5. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
8. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
[TBL] [Abstract][Full Text] [Related]
9. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
[TBL] [Abstract][Full Text] [Related]
10. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Shinoda K; Nakagawa K; Kosaka T; Tanaka N; Maeda T; Kono H; Mizuno R; Kikuchi E; Miyajima A; Umezawa K; Oya M
Hum Immunol; 2010 Aug; 71(8):763-70. PubMed ID: 20573582
[TBL] [Abstract][Full Text] [Related]
11. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
12. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Suzuki E; Ninomiya Y; Umezawa K
Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
[TBL] [Abstract][Full Text] [Related]
13. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Lampiasi N; Azzolina A; Umezawa K; Montalto G; McCubrey JA; Cervello M
Cancer Lett; 2012 Sep; 322(1):35-44. PubMed ID: 22343223
[TBL] [Abstract][Full Text] [Related]
14. Bidirectional regulation of NF-κB by reactive oxygen species: a role of unfolded protein response.
Nakajima S; Kitamura M
Free Radic Biol Med; 2013 Dec; 65():162-174. PubMed ID: 23792277
[TBL] [Abstract][Full Text] [Related]
15. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
16. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
Watanabe M; Yamashita K; Kamachi H; Kuraya D; Koshizuka Y; Shibasaki S; Asahi Y; Ono H; Emoto S; Ogura M; Yoshida T; Ozaki M; Umezawa K; Matsushita M; Todo S
Transplantation; 2013 Sep; 96(5):454-62. PubMed ID: 23860082
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Kuraya D; Watanabe M; Koshizuka Y; Ogura M; Yoshida T; Asahi Y; Kamachi H; Nakamura T; Harashima H; Ozaki M; Umezawa K; Matsushita M; Yamashita K; Todo S
Transplantation; 2013 Sep; 96(5):445-53. PubMed ID: 23900151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
